The data revealed that Remodelin significantly reduced AR-negative prostate cancer tumor growth, and in the high-dose Remodelin group, xenograft tumor weight at the endpoint was also much smaller than that in the low-dose group (Figure 1G). This evidence concerns the gene AR and neoplasm.